ImmunOs Therapeutics AG Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.
Tag Archive for: tumour microenvironment
King's CollegeA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.